Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$139.16 -1.7%	$141.91	$128.51 ▼ $238.00	$20.37B	0.01	1.25 million shs	1.77 million shs
MU Micron Technology	$94.18 -2.8%	$96.80	$83.54 ▼ $157.54	$104.93B	1.23	22.39 million shs	22.16 million shs
REGN Regeneron Pharmaceuticals	$634.14 -4.1%	$687.18	$633.10 ▼ $1,211.20	$69.33B	0.27	637,643 shs	852,346 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	+0.50%	-1.35%	+0.68%	-4.98%	-35.08%
MU Micron Technology	+2.34%	-5.98%	-1.87%	+8.58%	-12.04%
REGN Regeneron Pharmaceuticals	+0.38%	-2.57%	-5.62%	-7.48%	-31.66%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.8475 of 5 stars	4.2	4.0	0.0	3.7	2.9	2.5	1.9
MU Micron Technology	4.9437 of 5 stars	4.4	5.0	1.7	1.8	2.1	2.5	2.5
REGN Regeneron Pharmaceuticals	4.8596 of 5 stars	4.4	3.0	1.7	2.3	4.1	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.43	Hold	$213.33	53.30% Upside
MU Micron Technology	2.88	Moderate Buy	$132.63	40.82% Upside
REGN Regeneron Pharmaceuticals	2.76	Moderate Buy	$973.13	53.46% Upside

Current Analyst Ratings Breakdown

Latest MU, REGN, and BIIB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/21/2025	MU Micron Technology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $120.00
3/21/2025	MU Micron Technology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$110.00 ➝ $115.00
3/21/2025	MU Micron Technology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$145.00 ➝ $135.00
3/21/2025	MU Micron Technology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$130.00 ➝ $130.00
3/21/2025	MU Micron Technology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$91.00 ➝ $112.00
3/21/2025	MU Micron Technology	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$250.00 ➝ $200.00
3/21/2025	MU Micron Technology	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $163.00
3/17/2025	MU Micron Technology	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$125.00 ➝ $130.00
3/17/2025	MU Micron Technology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$125.00 ➝ $125.00
3/13/2025	MU Micron Technology	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$140.00 ➝ $130.00
2/18/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$138.00 ➝ $135.00

(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.68B	2.11	$22.85 per share	6.09	$114.71 per share	1.21
MU Micron Technology	$31.32B	3.35	$6.94 per share	13.57	$40.71 per share	2.31
REGN Regeneron Pharmaceuticals	$14.20B	4.88	$41.64 per share	15.23	$268.50 per share	2.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$11.19	12.44	8.43	1.51	16.87%	14.98%	8.76%	4/23/2025 (Estimated)
MU Micron Technology	$778M	$4.17	27.14	8.83	N/A	13.34%	8.32%	5.49%	N/A
REGN Regeneron Pharmaceuticals	$4.41B	$38.28	16.57	16.68	2.34	31.07%	16.32%	12.76%	5/1/2025 (Estimated)

Latest MU, REGN, and BIIB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/20/2025	Q2 2025	MU Micron Technology	$1.43	$1.56	+$0.13	$1.41	$7.93 billion	$8.05 billion
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A
2/4/2025	Q4 24	REGN Regeneron Pharmaceuticals	$11.21	$12.07	+$0.86	$8.06	$3.76 billion	$3.79 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
MU Micron Technology	$0.46	0.49%	+32.00%	11.03%	N/A
REGN Regeneron Pharmaceuticals	$0.88	0.14%	N/A	2.30%	N/A

Latest MU, REGN, and BIIB Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/20/2025	MU Micron Technology	quarterly	$0.1150	0.5%	3/31/2025	3/31/2025	4/15/2025
2/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.53%	2/20/2025	2/20/2025	3/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.27	1.35	0.90
MU Micron Technology	0.28	2.72	1.75
REGN Regeneron Pharmaceuticals	0.09	4.73	3.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
MU Micron Technology	80.84%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.16%
MU Micron Technology	0.30%
REGN Regeneron Pharmaceuticals	7.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	8,720	146.38 million	146.14 million	Optionable
MU Micron Technology	48,000	1.11 billion	1.11 billion	Optionable
REGN Regeneron Pharmaceuticals	11,900	109.33 million	101.15 million	Optionable

MU, REGN, and BIIB Headlines

Recent News About These Companies

Is Regeneron Pharmaceuticals, Inc. (REGN) a Promising Biotech Stock According to Wall Street Analysts

March 25 at 7:40 PM | msn.com

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

March 25 at 4:05 PM | globenewswire.com

Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Extremely Profitable Stocks to Buy According to Analyst?

March 25 at 10:34 AM | insidermonkey.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Corebridge Financial Inc.

March 25 at 6:31 AM | marketbeat.com

Vanguard Group Inc. Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 25 at 5:44 AM | marketbeat.com

Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation

March 24 at 11:13 PM | globenewswire.com

Simplify Asset Management Inc. Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 24 at 6:18 AM | marketbeat.com

KLP Kapitalforvaltning AS Makes New $34.47 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 24 at 5:49 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Mizuho Securities USA LLC

March 24 at 5:25 AM | marketbeat.com

AXQ Capital LP Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 24 at 5:18 AM | marketbeat.com

Forefront Wealth Management Inc. Acquires New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 23 at 6:34 AM | marketbeat.com

American Century Companies Inc. Sells 30,949 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 23 at 6:33 AM | marketbeat.com

Virtu Financial LLC Has $3.06 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 23 at 6:09 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Summit Global Investments

March 23 at 5:49 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Teacher Retirement System of Texas

March 23 at 4:57 AM | marketbeat.com

Madison Investment Advisors LLC Takes $4.59 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 23 at 3:53 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

March 23 at 3:44 AM | marketbeat.com

DCF Advisers LLC Has $6.34 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 22 at 6:05 AM | marketbeat.com

Commonwealth of Pennsylvania Public School Empls Retrmt SYS Cuts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 22 at 5:22 AM | marketbeat.com

iA Global Asset Management Inc. Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 22 at 5:21 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Royal London Asset Management Ltd.

March 22 at 5:11 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

4 EV Stocks Facing Uncertainty—Which Ones Will Survive?
By Thomas Hughes | March 7, 2025
View 4 EV Stocks Facing Uncertainty—Which Ones Will Survive?
These 3 Tech Stocks Are Gaining Steam After NVIDIA’s Report
By Gabriel Osorio-Mazilli | March 3, 2025
View These 3 Tech Stocks Are Gaining Steam After NVIDIA’s Report
One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
By Gabriel Osorio-Mazilli | March 9, 2025
View One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
By Jeffrey Neal Johnson | February 28, 2025
View 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
By Jeffrey Neal Johnson | February 25, 2025
View NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times

MU, REGN, and BIIB Company Descriptions

Biogen NASDAQ:BIIB

$139.16 -2.44 (-1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$139.96 +0.80 (+0.57%)

As of 07:46 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Micron Technology NASDAQ:MU

$94.18 -2.76 (-2.85%)

Closing price 04:00 PM Eastern

Extended Trading

$94.32 +0.14 (+0.15%)

As of 07:59 PM Eastern

Micron Technology, Inc. designs, develops, manufactures, and sells memory and storage products worldwide. The company operates through four segments: Compute and Networking Business Unit, Mobile Business Unit, Embedded Business Unit, and Storage Business Unit. It provides memory and storage technologies comprising dynamic random access memory semiconductor devices with low latency that provide high-speed data retrieval; non-volatile and re-writeable semiconductor storage devices; and non-volatile re-writable semiconductor memory devices that provide fast read speeds under the Micron and Crucial brands, as well as through private labels. The company offers memory products for the cloud server, enterprise, client, graphics, networking, industrial, and automotive markets, as well as for smartphone and other mobile-device markets; SSDs and component-level solutions for the enterprise and cloud, client, and consumer storage markets; discrete storage products in component and wafers; and memory and storage products for the automotive, industrial, and consumer markets. It markets its products through its direct sales force, independent sales representatives, distributors, and retailers; and web-based customer direct sales channel, as well as through channel and distribution partners. Micron Technology, Inc. was founded in 1978 and is headquartered in Boise, Idaho.

Regeneron Pharmaceuticals NASDAQ:REGN

$634.14 -26.86 (-4.06%)

Closing price 04:00 PM Eastern

Extended Trading

$635.49 +1.35 (+0.21%)

As of 07:59 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time